ArticleHepatology (Baltimore, Md.)2012
Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.
Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- BIM and NOXA are mitochondrial effectors of TAF6δ-driven apoptosis.Cell death & disease · 2018Article
- β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development.Scientific reports · 2017Article
- Genomic Signatures of Emerging Viruses: A New Era of Systems Epidemiology.Cell host & microbe · 2016Review
- Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.The American journal of gastroenterology · 2015Article
- Alternative splicing of TAF6: downstream transcriptome impacts and upstream RNA splice control elements.PloS one · 2014Article
- Systems virology: host-directed approaches to viral pathogenesis and drug targeting.Nature reviews. Microbiology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
unlabelledLiver failure resulting from chronic hepatitis C virus (HCV) infection is a major cause for liver transplantation worldwide. Recurrent infection of the graft is universal in HCV patients after transplant and results in a rapid progression to severe fibrosis and end-stage liver disease in one third of all patients. No single clinical variable, or combination thereof, has, so far, proven accurate in identifying patients at risk of hepatic decompensation in the transplant setting. A combination of longitudinal, dimensionality reduction and categorical analysis of the transcriptome from 111 liver biopsy specimens taken from 57 HCV-infected patients over time identified a molecular signature of gene expression of patients at risk of developing severe fibrosis. Significantly, alterations in gene expression occur before histologic evidence of liver disease progression, suggesting that events that occur during the acute phase of infection influence patient outcome. Additionally, a common precursor state for different severe clinical outcomes was identified.
conclusionBased on this patient cohort, incidence of severe liver disease is a process initiated early during HCV infection of the donor organ. The probable cellular network at the basis of the initial transition to severe liver disease was identified and characterized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.